Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Focus Minnesota.
Press releases published on October 23, 2025
Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke
Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and well-tolerated, with no increase in …
Hydreight Reports Corporate Update and Ranks #25 on Deloitte’s 2025 Technology Fast 50™
Over 295,000 VSDHOne product orders between July and September, accelerating nurse network growth and a strong balance sheet with approximately CA$18.7 million in cash; Hydreight continues to build the infrastructure for compliant, nationwide digital …
Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors
-- First-in-class non-oncolytic arenavirus-based approach designed to induce targeted, effective, and durable anti-cancer activity against primary tumors and metastases – -- Phase 1 study to evaluate the safety and tolerability of ABX-001 and determine the …
NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies
STEVENAGE, United Kingdom, Oct. 23, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the addition …
Vantage Hemp Co. Strengthens Global Footprint with Initiation of European Regulatory Filings
Greeley, Colorado, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Vantage Hemp Co. (“Vantage” or “the Company”), a globally accredited cannabinoid manufacturer, has initiated the submission process for its Certificate of Suitability (CEP) to the European Directorate …
RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER
NEWS RELEASE Milan, 23 October 2025 – Recordati, a global pharmaceutical company, announces today that Mike McClellan will join as its new Chief Financial Officer (CFO) as of January 1, 2026 and will be based in the Group’s headquarters in Milan. Mike …
Nicox Provides First Half 2025 Financial Results
New Drug Application (NDA) submissions for NCX 470 expected in 2026 in the U.S. and China Company believes that it can finance its existing operations for at least 12 months and expects to fully repay existing financial debts in 2026 October 23, 2025 – …
Nicox : Résultats financiers du premier semestre 2025
23 octobre 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui les résultats financiers de Nicox SA (la « …
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an expansion of their partnership to bolster clinical research. This …
Cannabix Technologies announces Stock Option Grant
VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports it has granted 2,500,000 incentive stock options (“the Options”) to certain …
BrightCraft Dental Announces Comprehensive Sedation and Digital Full-Arch Transformation Model in Burbank
BURBANK, CA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- BrightCraft Dental announced the launch of its new transformative care model centered on sedation (“sleep dentistry”), digital implant planning, and full-arch restorative solutions at its Burbank practice. …
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
— First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating related toxicities — — Unique, highly potent PI3K/PIKK inhibitor payload optimized to exploit antibody-conjugate …